[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU758406B2 - Vectors for transferring nucleic acids, compositions containing them and their uses - Google Patents

Vectors for transferring nucleic acids, compositions containing them and their uses Download PDF

Info

Publication number
AU758406B2
AU758406B2 AU34062/00A AU3406200A AU758406B2 AU 758406 B2 AU758406 B2 AU 758406B2 AU 34062/00 A AU34062/00 A AU 34062/00A AU 3406200 A AU3406200 A AU 3406200A AU 758406 B2 AU758406 B2 AU 758406B2
Authority
AU
Australia
Prior art keywords
vector
nucleic acids
sequence
oligonucleotide
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34062/00A
Other languages
English (en)
Other versions
AU3406200A (en
Inventor
Carole Ciolina
Daniel Schermann
Pierre Wils
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9803573A external-priority patent/FR2776669B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU3406200A publication Critical patent/AU3406200A/en
Application granted granted Critical
Publication of AU758406B2 publication Critical patent/AU758406B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU34062/00A 1998-03-24 2000-05-12 Vectors for transferring nucleic acids, compositions containing them and their uses Ceased AU758406B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9803573A FR2776669B1 (fr) 1998-03-24 1998-03-24 Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
FR9803573 1998-03-24
US8584898P 1998-05-18 1998-05-18
US60/085848 1998-05-18

Publications (2)

Publication Number Publication Date
AU3406200A AU3406200A (en) 2000-12-14
AU758406B2 true AU758406B2 (en) 2003-03-20

Family

ID=26234216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34062/00A Ceased AU758406B2 (en) 1998-03-24 2000-05-12 Vectors for transferring nucleic acids, compositions containing them and their uses

Country Status (12)

Country Link
EP (1) EP1066396A1 (fr)
JP (1) JP2002507429A (fr)
KR (1) KR20010074456A (fr)
CN (1) CN1292827A (fr)
AU (1) AU758406B2 (fr)
BR (1) BR9909044A (fr)
CA (1) CA2323831A1 (fr)
HU (1) HUP0102413A3 (fr)
IL (1) IL138624A0 (fr)
NO (1) NO20004648L (fr)
PL (1) PL342944A1 (fr)
WO (1) WO1999049067A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60132200T2 (de) * 2000-05-26 2008-12-18 Centelion Reinigung einer tripelhelixformation mittels eines immobilisierten oligonukleotides
FR2871465B1 (fr) * 2004-06-15 2006-09-08 Centre Nat Rech Scient Cnrse Collections de composes tracables et leurs utilisations
WO2006133099A2 (fr) * 2005-06-03 2006-12-14 The Cbr Institute For Biomedical Research, Inc. Microbicides d'arnic pour prevenir et pour traiter des maladies
US7795380B2 (en) 2006-06-02 2010-09-14 University Of Iowa Research Foundation Compositions and methods for nucleic acid delivery
WO2017156038A2 (fr) * 2016-03-07 2017-09-14 Alere San Diego, Inc. Étalons internes pour dosages immunologiques et leur utilisation
RU2731513C2 (ru) * 2018-12-21 2020-09-03 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов NOS2, NOS3, VIP, KCNMA1, CGRP, для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-NOS2, или Escherichia coli SCS110-AF/VTvaf17-NOS3, или Escherichia coli SCS110-AF/VTvaf17-VIP, или Escherichia coli SCS110-AF/VTvaf17-KCNMA1, или Escherichia coli SCS110-AF/VTvaf17-CGRP, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
WO2024206118A1 (fr) * 2023-03-24 2024-10-03 Yarrow Therapeutics, Inc. Polypeptides et conjugués de localisation nucléaire et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020698A1 (fr) * 1991-05-17 1992-11-26 Uab Research Foundation Medicaments liant l'adn de maniere specifique a une sequence
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique

Also Published As

Publication number Publication date
EP1066396A1 (fr) 2001-01-10
IL138624A0 (en) 2001-10-31
JP2002507429A (ja) 2002-03-12
NO20004648D0 (no) 2000-09-18
KR20010074456A (ko) 2001-08-04
NO20004648L (no) 2000-09-18
HUP0102413A3 (en) 2003-09-29
WO1999049067A1 (fr) 1999-09-30
CA2323831A1 (fr) 1999-09-30
PL342944A1 (en) 2001-07-16
BR9909044A (pt) 2000-12-05
CN1292827A (zh) 2001-04-25
AU3406200A (en) 2000-12-14
HUP0102413A1 (hu) 2001-10-28

Similar Documents

Publication Publication Date Title
AU773242B2 (en) Genetic alteration in plants using single-stranded oligonucleotide vectors
US5945400A (en) Nucleic acid-containing composition, preparation and use thereof
US6013240A (en) Nucleic acid containing composition, preparation and uses of same
EP0759694B1 (fr) Procede pour l'administration in vivo d'agents therapeutiques par des liposomes
KR100377889B1 (ko) 핵산을함유하는조성물,제조및용도
US5843643A (en) Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
KR19980702406A (ko) 디엔에이분자, 이의 제조방법 및 유전자 치료에 있어서의 이의 용도
KR20010020375A (ko) 간세포에서 유전적 병소를 교정하기 위한 재조합에 의해 만들어진 올리고뉴클레오염기의 ｉｎ ｖｉｖｏ에서의 용도
JP2022516647A (ja) 非毒性ｃａｓ９酵素およびその用途
AU758406B2 (en) Vectors for transferring nucleic acids, compositions containing them and their uses
EP1013770A1 (fr) Vecteur de transfection non-viral
MXPA00009046A (en) Nucleic acid transfer vectors, compositions containing same and uses
FR2776669A1 (fr) Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
CZ20003441A3 (cs) Vektory pro přenos nukleových kyselin, přípravky, které je obsahují a jejich použití
US20040063922A1 (en) Methods and compositions for catalytic DNA exchange in a sequence specific manner
KR20000010608A (ko) 티로신 하이드록실라제 유전자로부터 유도된 발현 시스템
AU737314B2 (en) Nucleic acid containing composition, preparation and uses of same
Phylactou et al. Utilization of properties of natural catalytic RNA to design and synthesize functional ribozymes

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 19990324 TO 20000512 IN WHICH TO CLAIM CONVENTION PRIORITY

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO CLAIM THE CONVENTION PRIORITY DATE HAS BEEN EXTENDED TO 20000512

FGA Letters patent sealed or granted (standard patent)